Drug-induced liver toxicity:
This book provides a comprehensive view of the methodologies used for the study of liver toxicity encountered throughout the whole life cycle of a drug, from drug discovery, to clinical trial, post-marketing, and even clinical practice. Organized into six sections, the first section introduces the m...
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
New York, NY
Springer New York
2018
|
| Ausgabe: | 1st ed. 2018 |
| Schriftenreihe: | Methods in Pharmacology and Toxicology
|
| Schlagworte: | |
| Online-Zugang: | UBR01 TUM01 URL des Erstveröffentlichers |
| Zusammenfassung: | This book provides a comprehensive view of the methodologies used for the study of liver toxicity encountered throughout the whole life cycle of a drug, from drug discovery, to clinical trial, post-marketing, and even clinical practice. Organized into six sections, the first section introduces the mechanisms contributing to drug-induced liver toxicity. The second and third section explore in silico and in vitro approaches used to help mitigate hepatotoxicity liability at the early stages of drug development. The fourth section describes methodologies applied in regulatory processes, including preclinical studies, clinical trials, and post-marketing surveillance. The fifth section discusses clinical hepatotoxicity. Emerging technologies are examined in the final section. As a volume in the Methods in Pharmacology and Toxicology series, chapters include the kind of expert advice that will lead to optimal results. Authoritative and practical, Drug-Induced Liver Toxicity serves all those who aim to improve assessment and understanding of hepatotoxic potentials of new medications and marketed drugs. Chapter 30 is open access under a CC BY 4.0 license via link.springer.com. |
| Beschreibung: | Overview of Mechanisms of Drug-Induced Liver Injury (DILI) and Key Challenges in DILI Research -- Detection, Elimination, Mitigation, and Prediction of Drug-Induced Liver Injury in Drug Discovery -- Drug-Induced Liver Injury (DILI) Classification and Its Application on Human DILI Risk Prediction -- Physicochemical Properties and Structural Alerts -- Quantitative Structure-Activity Relationship Models for Predicting Risk of Drug-Induced Liver Injury in Humans -- An Introduction to DILIsym Software, a Mechanistic Mathematical Representation of Drug-Induced Liver Injury -- Prediction of Human Liver Toxicity Using In Vitro Assays: Limitations and Opportunities -- Use of Liver-Derived Cell Lines for the Study of Drug-Induced Liver Injury -- Evaluation of Drug-induced Liver Injuries (DILI) with Human Hepatocytes: Scientific Rationale and Experimental Approaches -- Status and Use of Induced Pluripotent Stem Cells (iPSCs) in Toxicity Testing -- - Engineered Human Liver Co-Cultures for Investigating Drug-Induced Liver Injury -- Status and Future of 3D Cell Culture in Toxicity Testing -- Reactive Metabolite Assessment in Drug Discovery and Development in Support of Safe Drug Design -- In Vitro Assessment of Mitochondrial Toxicity to Predict Drug-Induced Liver Injury -- Bile Salt Export Pump: Drug-Induced Liver Injury and Assessment Approaches -- High Content Screening for Prediction of Human Drug-Induced Liver Injury -- Interpretation, Integration, and Implementation of In Vitro Assay Data: The Predictive Toxicity Challenge -- Perspectives on the Regulatory and Clinical Science of Drug-Induced Liver Injury (DILI) -- Regulatory Toxicological Studies: Identifying Drug-Induced Liver Injury Using Nonclinical Studies -- Hy's Law and eDISH for Clinical Studies -- Variability in Baseline Liver Test Values in Clinical Trials: Challenges in Enhancing Drug-Induced Liver Injury Assessment in Subjects with Liver Disease -- - Postmarketing Surveillance of Drug-Induced Liver Injury -- Host Risk Modifiers in Idiosyncratic Drug-Induced Liver Injury (DILI) and Its Interplay with Drug Properties -- Human Leukocyte Antigen (HLA) and Other Genetic Risk Factors in Drug-Induced Liver Injury (DILI) -- Immune Mechanisms in Drug-Induced Liver Injury -- Translational and Mechanistic Biomarkers of Drug-Induced Liver Injury -- Causality Assessment Methods in Drug-Induced Liver Injury -- Circulating MicroRNAs as Novel Biomarkers of Drug-Induced Liver Injury in Humans -- Systems Microscopy Approaches in Unraveling and Predicting Drug-Induced Liver Injury (DILI) -- Non-Invasive Pre-Clinical and Clinical Imaging of Liver Transporter Function Relevant to Drug-Induced Liver Injury |
| Beschreibung: | 1 Online-Ressource (XX, 667 Seiten) Illustrationen |
| ISBN: | 9781493976775 |
| DOI: | 10.1007/978-1-4939-7677-5 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV047626926 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 211206s2018 |||| o||u| ||||||eng d | ||
| 020 | |a 9781493976775 |c Online |9 978-1-4939-7677-5 | ||
| 024 | 7 | |a 10.1007/978-1-4939-7677-5 |2 doi | |
| 035 | |a (ZDB-2-PRO)978-1-4939-7677-5 | ||
| 035 | |a (OCoLC)1289765808 | ||
| 035 | |a (DE-599)BVBBV047626926 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 |a DE-91 | ||
| 082 | 0 | |a 615 | |
| 245 | 1 | 0 | |a Drug-induced liver toxicity |c edited by Minjun Chen, Yvonne Will |
| 250 | |a 1st ed. 2018 | ||
| 264 | 1 | |a New York, NY |b Springer New York |c 2018 | |
| 300 | |a 1 Online-Ressource (XX, 667 Seiten) |b Illustrationen | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Methods in Pharmacology and Toxicology | |
| 500 | |a Overview of Mechanisms of Drug-Induced Liver Injury (DILI) and Key Challenges in DILI Research -- Detection, Elimination, Mitigation, and Prediction of Drug-Induced Liver Injury in Drug Discovery -- Drug-Induced Liver Injury (DILI) Classification and Its Application on Human DILI Risk Prediction -- Physicochemical Properties and Structural Alerts -- Quantitative Structure-Activity Relationship Models for Predicting Risk of Drug-Induced Liver Injury in Humans -- An Introduction to DILIsym Software, a Mechanistic Mathematical Representation of Drug-Induced Liver Injury -- Prediction of Human Liver Toxicity Using In Vitro Assays: Limitations and Opportunities -- Use of Liver-Derived Cell Lines for the Study of Drug-Induced Liver Injury -- Evaluation of Drug-induced Liver Injuries (DILI) with Human Hepatocytes: Scientific Rationale and Experimental Approaches -- Status and Use of Induced Pluripotent Stem Cells (iPSCs) in Toxicity Testing -- | ||
| 500 | |a - Engineered Human Liver Co-Cultures for Investigating Drug-Induced Liver Injury -- Status and Future of 3D Cell Culture in Toxicity Testing -- Reactive Metabolite Assessment in Drug Discovery and Development in Support of Safe Drug Design -- In Vitro Assessment of Mitochondrial Toxicity to Predict Drug-Induced Liver Injury -- Bile Salt Export Pump: Drug-Induced Liver Injury and Assessment Approaches -- High Content Screening for Prediction of Human Drug-Induced Liver Injury -- Interpretation, Integration, and Implementation of In Vitro Assay Data: The Predictive Toxicity Challenge -- Perspectives on the Regulatory and Clinical Science of Drug-Induced Liver Injury (DILI) -- Regulatory Toxicological Studies: Identifying Drug-Induced Liver Injury Using Nonclinical Studies -- Hy's Law and eDISH for Clinical Studies -- Variability in Baseline Liver Test Values in Clinical Trials: Challenges in Enhancing Drug-Induced Liver Injury Assessment in Subjects with Liver Disease -- | ||
| 500 | |a - Postmarketing Surveillance of Drug-Induced Liver Injury -- Host Risk Modifiers in Idiosyncratic Drug-Induced Liver Injury (DILI) and Its Interplay with Drug Properties -- Human Leukocyte Antigen (HLA) and Other Genetic Risk Factors in Drug-Induced Liver Injury (DILI) -- Immune Mechanisms in Drug-Induced Liver Injury -- Translational and Mechanistic Biomarkers of Drug-Induced Liver Injury -- Causality Assessment Methods in Drug-Induced Liver Injury -- Circulating MicroRNAs as Novel Biomarkers of Drug-Induced Liver Injury in Humans -- Systems Microscopy Approaches in Unraveling and Predicting Drug-Induced Liver Injury (DILI) -- Non-Invasive Pre-Clinical and Clinical Imaging of Liver Transporter Function Relevant to Drug-Induced Liver Injury | ||
| 520 | |a This book provides a comprehensive view of the methodologies used for the study of liver toxicity encountered throughout the whole life cycle of a drug, from drug discovery, to clinical trial, post-marketing, and even clinical practice. Organized into six sections, the first section introduces the mechanisms contributing to drug-induced liver toxicity. The second and third section explore in silico and in vitro approaches used to help mitigate hepatotoxicity liability at the early stages of drug development. The fourth section describes methodologies applied in regulatory processes, including preclinical studies, clinical trials, and post-marketing surveillance. The fifth section discusses clinical hepatotoxicity. Emerging technologies are examined in the final section. As a volume in the Methods in Pharmacology and Toxicology series, chapters include the kind of expert advice that will lead to optimal results. Authoritative and practical, Drug-Induced Liver Toxicity serves all those who aim to improve assessment and understanding of hepatotoxic potentials of new medications and marketed drugs. Chapter 30 is open access under a CC BY 4.0 license via link.springer.com. | ||
| 650 | 4 | |a Pharmacology | |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 700 | 1 | |a Chen, Minjun |4 edt | |
| 700 | 1 | |a Will, Yvonne |0 (DE-588)115502737X |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781493976768 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781493976782 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781493992560 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-1-4939-7677-5 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-PRO | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-033011411 | ||
| 966 | e | |u https://doi.org/10.1007/978-1-4939-7677-5 |l UBR01 |p ZDB-2-PRO |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1007/978-1-4939-7677-5 |l TUM01 |p ZDB-2-PRO |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804183069655040000 |
|---|---|
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author2 | Chen, Minjun Will, Yvonne |
| author2_role | edt edt |
| author2_variant | m c mc y w yw |
| author_GND | (DE-588)115502737X |
| author_facet | Chen, Minjun Will, Yvonne |
| building | Verbundindex |
| bvnumber | BV047626926 |
| collection | ZDB-2-PRO |
| ctrlnum | (ZDB-2-PRO)978-1-4939-7677-5 (OCoLC)1289765808 (DE-599)BVBBV047626926 |
| dewey-full | 615 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615 |
| dewey-search | 615 |
| dewey-sort | 3615 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| doi_str_mv | 10.1007/978-1-4939-7677-5 |
| edition | 1st ed. 2018 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05575nmm a2200481zc 4500</leader><controlfield tag="001">BV047626926</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">211206s2018 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781493976775</subfield><subfield code="c">Online</subfield><subfield code="9">978-1-4939-7677-5</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-1-4939-7677-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-PRO)978-1-4939-7677-5</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1289765808</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV047626926</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-91</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Drug-induced liver toxicity</subfield><subfield code="c">edited by Minjun Chen, Yvonne Will</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1st ed. 2018</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York, NY</subfield><subfield code="b">Springer New York</subfield><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XX, 667 Seiten)</subfield><subfield code="b">Illustrationen</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Methods in Pharmacology and Toxicology</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Overview of Mechanisms of Drug-Induced Liver Injury (DILI) and Key Challenges in DILI Research -- Detection, Elimination, Mitigation, and Prediction of Drug-Induced Liver Injury in Drug Discovery -- Drug-Induced Liver Injury (DILI) Classification and Its Application on Human DILI Risk Prediction -- Physicochemical Properties and Structural Alerts -- Quantitative Structure-Activity Relationship Models for Predicting Risk of Drug-Induced Liver Injury in Humans -- An Introduction to DILIsym Software, a Mechanistic Mathematical Representation of Drug-Induced Liver Injury -- Prediction of Human Liver Toxicity Using In Vitro Assays: Limitations and Opportunities -- Use of Liver-Derived Cell Lines for the Study of Drug-Induced Liver Injury -- Evaluation of Drug-induced Liver Injuries (DILI) with Human Hepatocytes: Scientific Rationale and Experimental Approaches -- Status and Use of Induced Pluripotent Stem Cells (iPSCs) in Toxicity Testing -- </subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a"> - Engineered Human Liver Co-Cultures for Investigating Drug-Induced Liver Injury -- Status and Future of 3D Cell Culture in Toxicity Testing -- Reactive Metabolite Assessment in Drug Discovery and Development in Support of Safe Drug Design -- In Vitro Assessment of Mitochondrial Toxicity to Predict Drug-Induced Liver Injury -- Bile Salt Export Pump: Drug-Induced Liver Injury and Assessment Approaches -- High Content Screening for Prediction of Human Drug-Induced Liver Injury -- Interpretation, Integration, and Implementation of In Vitro Assay Data: The Predictive Toxicity Challenge -- Perspectives on the Regulatory and Clinical Science of Drug-Induced Liver Injury (DILI) -- Regulatory Toxicological Studies: Identifying Drug-Induced Liver Injury Using Nonclinical Studies -- Hy's Law and eDISH for Clinical Studies -- Variability in Baseline Liver Test Values in Clinical Trials: Challenges in Enhancing Drug-Induced Liver Injury Assessment in Subjects with Liver Disease -- </subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a"> - Postmarketing Surveillance of Drug-Induced Liver Injury -- Host Risk Modifiers in Idiosyncratic Drug-Induced Liver Injury (DILI) and Its Interplay with Drug Properties -- Human Leukocyte Antigen (HLA) and Other Genetic Risk Factors in Drug-Induced Liver Injury (DILI) -- Immune Mechanisms in Drug-Induced Liver Injury -- Translational and Mechanistic Biomarkers of Drug-Induced Liver Injury -- Causality Assessment Methods in Drug-Induced Liver Injury -- Circulating MicroRNAs as Novel Biomarkers of Drug-Induced Liver Injury in Humans -- Systems Microscopy Approaches in Unraveling and Predicting Drug-Induced Liver Injury (DILI) -- Non-Invasive Pre-Clinical and Clinical Imaging of Liver Transporter Function Relevant to Drug-Induced Liver Injury</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This book provides a comprehensive view of the methodologies used for the study of liver toxicity encountered throughout the whole life cycle of a drug, from drug discovery, to clinical trial, post-marketing, and even clinical practice. Organized into six sections, the first section introduces the mechanisms contributing to drug-induced liver toxicity. The second and third section explore in silico and in vitro approaches used to help mitigate hepatotoxicity liability at the early stages of drug development. The fourth section describes methodologies applied in regulatory processes, including preclinical studies, clinical trials, and post-marketing surveillance. The fifth section discusses clinical hepatotoxicity. Emerging technologies are examined in the final section. As a volume in the Methods in Pharmacology and Toxicology series, chapters include the kind of expert advice that will lead to optimal results. Authoritative and practical, Drug-Induced Liver Toxicity serves all those who aim to improve assessment and understanding of hepatotoxic potentials of new medications and marketed drugs. Chapter 30 is open access under a CC BY 4.0 license via link.springer.com.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacology</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Minjun</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Will, Yvonne</subfield><subfield code="0">(DE-588)115502737X</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781493976768</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781493976782</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781493992560</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-1-4939-7677-5</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-PRO</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033011411</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-4939-7677-5</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-PRO</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-4939-7677-5</subfield><subfield code="l">TUM01</subfield><subfield code="p">ZDB-2-PRO</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV047626926 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T18:44:32Z |
| indexdate | 2024-07-10T09:17:35Z |
| institution | BVB |
| isbn | 9781493976775 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033011411 |
| oclc_num | 1289765808 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-91 DE-BY-TUM |
| owner_facet | DE-355 DE-BY-UBR DE-91 DE-BY-TUM |
| physical | 1 Online-Ressource (XX, 667 Seiten) Illustrationen |
| psigel | ZDB-2-PRO |
| publishDate | 2018 |
| publishDateSearch | 2018 |
| publishDateSort | 2018 |
| publisher | Springer New York |
| record_format | marc |
| series2 | Methods in Pharmacology and Toxicology |
| spelling | Drug-induced liver toxicity edited by Minjun Chen, Yvonne Will 1st ed. 2018 New York, NY Springer New York 2018 1 Online-Ressource (XX, 667 Seiten) Illustrationen txt rdacontent c rdamedia cr rdacarrier Methods in Pharmacology and Toxicology Overview of Mechanisms of Drug-Induced Liver Injury (DILI) and Key Challenges in DILI Research -- Detection, Elimination, Mitigation, and Prediction of Drug-Induced Liver Injury in Drug Discovery -- Drug-Induced Liver Injury (DILI) Classification and Its Application on Human DILI Risk Prediction -- Physicochemical Properties and Structural Alerts -- Quantitative Structure-Activity Relationship Models for Predicting Risk of Drug-Induced Liver Injury in Humans -- An Introduction to DILIsym Software, a Mechanistic Mathematical Representation of Drug-Induced Liver Injury -- Prediction of Human Liver Toxicity Using In Vitro Assays: Limitations and Opportunities -- Use of Liver-Derived Cell Lines for the Study of Drug-Induced Liver Injury -- Evaluation of Drug-induced Liver Injuries (DILI) with Human Hepatocytes: Scientific Rationale and Experimental Approaches -- Status and Use of Induced Pluripotent Stem Cells (iPSCs) in Toxicity Testing -- - Engineered Human Liver Co-Cultures for Investigating Drug-Induced Liver Injury -- Status and Future of 3D Cell Culture in Toxicity Testing -- Reactive Metabolite Assessment in Drug Discovery and Development in Support of Safe Drug Design -- In Vitro Assessment of Mitochondrial Toxicity to Predict Drug-Induced Liver Injury -- Bile Salt Export Pump: Drug-Induced Liver Injury and Assessment Approaches -- High Content Screening for Prediction of Human Drug-Induced Liver Injury -- Interpretation, Integration, and Implementation of In Vitro Assay Data: The Predictive Toxicity Challenge -- Perspectives on the Regulatory and Clinical Science of Drug-Induced Liver Injury (DILI) -- Regulatory Toxicological Studies: Identifying Drug-Induced Liver Injury Using Nonclinical Studies -- Hy's Law and eDISH for Clinical Studies -- Variability in Baseline Liver Test Values in Clinical Trials: Challenges in Enhancing Drug-Induced Liver Injury Assessment in Subjects with Liver Disease -- - Postmarketing Surveillance of Drug-Induced Liver Injury -- Host Risk Modifiers in Idiosyncratic Drug-Induced Liver Injury (DILI) and Its Interplay with Drug Properties -- Human Leukocyte Antigen (HLA) and Other Genetic Risk Factors in Drug-Induced Liver Injury (DILI) -- Immune Mechanisms in Drug-Induced Liver Injury -- Translational and Mechanistic Biomarkers of Drug-Induced Liver Injury -- Causality Assessment Methods in Drug-Induced Liver Injury -- Circulating MicroRNAs as Novel Biomarkers of Drug-Induced Liver Injury in Humans -- Systems Microscopy Approaches in Unraveling and Predicting Drug-Induced Liver Injury (DILI) -- Non-Invasive Pre-Clinical and Clinical Imaging of Liver Transporter Function Relevant to Drug-Induced Liver Injury This book provides a comprehensive view of the methodologies used for the study of liver toxicity encountered throughout the whole life cycle of a drug, from drug discovery, to clinical trial, post-marketing, and even clinical practice. Organized into six sections, the first section introduces the mechanisms contributing to drug-induced liver toxicity. The second and third section explore in silico and in vitro approaches used to help mitigate hepatotoxicity liability at the early stages of drug development. The fourth section describes methodologies applied in regulatory processes, including preclinical studies, clinical trials, and post-marketing surveillance. The fifth section discusses clinical hepatotoxicity. Emerging technologies are examined in the final section. As a volume in the Methods in Pharmacology and Toxicology series, chapters include the kind of expert advice that will lead to optimal results. Authoritative and practical, Drug-Induced Liver Toxicity serves all those who aim to improve assessment and understanding of hepatotoxic potentials of new medications and marketed drugs. Chapter 30 is open access under a CC BY 4.0 license via link.springer.com. Pharmacology (DE-588)4143413-4 Aufsatzsammlung gnd-content Chen, Minjun edt Will, Yvonne (DE-588)115502737X edt Erscheint auch als Druck-Ausgabe 9781493976768 Erscheint auch als Druck-Ausgabe 9781493976782 Erscheint auch als Druck-Ausgabe 9781493992560 https://doi.org/10.1007/978-1-4939-7677-5 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Drug-induced liver toxicity Pharmacology |
| subject_GND | (DE-588)4143413-4 |
| title | Drug-induced liver toxicity |
| title_auth | Drug-induced liver toxicity |
| title_exact_search | Drug-induced liver toxicity |
| title_exact_search_txtP | Drug-induced liver toxicity |
| title_full | Drug-induced liver toxicity edited by Minjun Chen, Yvonne Will |
| title_fullStr | Drug-induced liver toxicity edited by Minjun Chen, Yvonne Will |
| title_full_unstemmed | Drug-induced liver toxicity edited by Minjun Chen, Yvonne Will |
| title_short | Drug-induced liver toxicity |
| title_sort | drug induced liver toxicity |
| topic | Pharmacology |
| topic_facet | Pharmacology Aufsatzsammlung |
| url | https://doi.org/10.1007/978-1-4939-7677-5 |
| work_keys_str_mv | AT chenminjun druginducedlivertoxicity AT willyvonne druginducedlivertoxicity |